Sunday 18 October 2026
Export CABA’s income statement to Excel — free account
Cabaletta Bio, Inc.
CABA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 53.4% and free cash flow fell 35.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.41
0.14
−9.03%
Follow CABA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(101.06%) | (126.98%) | (156.03%) | (93.20%) | |
| (80.43%) | (95.88%) | (111.99%) | (75.36%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(131.13%) | (185.19%) | (212.91%) | (94.14%) | |
Free Cash Flow per Share |
(1.18) | (1.66) | (1.28) | (1.02) | |
Free Cash Flow |
(120.26) | (132.31) | (142.84) | (153.93) | |
Capital Expenditures |
(1.40) | (1.23) | — | — | |
| Other line items | |||||
Cash ROIC |
(40.17%) | (53.86%) | (64.94%) | (35.33%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(44.54) | (85.95) | (76.47) | (80.94) | |
Operating CF/Net income |
0.75 | 0.78 | 0.81 | 0.85 | |
Depreciation/Fixed assets |
2.04 | 6.41 | 7.39 | 7.85 | |
Capex/Depreciation |
(0.33) | (0.10) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.16) | (1.64) | (1.28) | (1.02) | |
Capex per Share |
(0.01) | (0.02) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates